Ascelia Pharma AB (publ)
Research Ascelia Pharma AB (publ) (ACE) on Bullrun: market cap SEK 391.26M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACE
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 391.26M
- Financial periodQ4 2025
- Net income-SEK 15.87M
- Free cash flow-SEK 21.69M
Valuation Snapshot
latest market cap is SEK 391.26M.
About Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc.
Frequently asked questions
What is Ascelia Pharma AB (publ)'s market cap?
Ascelia Pharma AB (publ)'s market capitalization is SEK 391.26M.
What does Ascelia Pharma AB (publ) do?
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver;